Updated on 12 July 2012
Oramed's portfolio consists of four issued patents and 33 patents pending for its technologies and products
Singapore: The New Zealand Patent Office granted Oramed Pharmaceuticals, a developer of oral drug delivery systems, a patent on "Methods and Compositions for Oral Administrations of Proteins". This patent covers a core concept in the company's technology and is Oramed's second patent to be granted in New Zealand, the first being that of its "Methods in the Oral Administration of Exenatide".
Oramed's portfolio now consists of four issued patents and 33 patents pending for its technologies and products. The current method of administration for peptide-formulated medications is most often via injection. The ability to administer these medications orally offers far-reaching impact on patient compliance and health costs with potential to traverse a broad range of ailments and drug therapies, including diabetes medications, vaccines, and others.
Oramed is currently applying its oral delivery technology to its two flagship products - an oral insulin capsule (ORMD-0801) and an oral GLP-1 analog capsule (ORMD-0901) - both of which are indicated for diabetes.